Search

Your search keyword '"Nur Aksoy"' showing total 2 results
Start Over Author "Nur Aksoy" Publisher biomed central
2 results on '"Nur Aksoy"'

1. Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities

Author

Rajabi, Hadi; Konyalılar, Nur; Aksoy, Gizem Tuse; Erkan, Sinem; Korkunç, Seval Tuba; Kayalar, Özgecan; Bayram, Hasan (ORCID 0000-0002-5236-766X & YÖK ID 4890), Rahbarghazi, Reza, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine; Graduate School of Health Sciences, Rajabi, Hadi; Konyalılar, Nur; Aksoy, Gizem Tuse; Erkan, Sinem; Korkunç, Seval Tuba; Kayalar, Özgecan; Bayram, Hasan (ORCID 0000-0002-5236-766X & YÖK ID 4890), Rahbarghazi, Reza, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine; Graduate School of Health Sciences

Abstract

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been growing swiftly worldwide. Patients with background chronic pulmonary inflammations such as asthma or chronic obstructive pulmonary diseases (COPD) are likely to be infected with this virus. Of note, there is an argument that COVID-19 can remain with serious complications like fibrosis or other pathological changes in the pulmonary tissue of patients with chronic diseases. Along with conventional medications, regenerative medicine, and cell-based therapy could be alternative approaches to compensate for organ loss or restore injured sites using different stem cell types. Owing to unique differentiation capacity and paracrine activity, these cells can accelerate the healing procedure. In this review article, we have tried to scrutinize different reports related to the harmful effects of SARS-CoV-2 on patients with asthma and COPD, as well as the possible therapeutic effects of stem cells in the alleviation of post-COVID-19 complications., This study was supported by a grant from Koc University Translational Medicine Research Center (KUTTAM).

Published
2022

2. Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy?

Author

Tabur, Suzan, Korkmaz, Hakan, Ozkaya, Mesut, Sefika Nur Aksoy, and Akarsu, Ersin

Subjects
SEROLOGY, NEUROPATHY, LOW density lipoproteins, CONTROL groups, BIOMARKERS
Abstract

Background: In the present study, we aimed to investigate serum calprotectin levels in patients with diabetic peripheral neuropathy, and possible role of this molecule in the disease pathogenesis. Method: Twenty nine patients with diabetic peripheral neuropathy, 30 type 2 diabetic patients without neuropathy, and 40 healthy controls were enrolled in the study. Fasting plasma glucose (FPG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), total cholesterol, triglyceride, HbA1c, calprotectin and hsCRP levels were measured in diabetic and healthy control groups. Results: Serum calprotectin and hsCRP levels were significantly higher in patients with and without neuropathy than healthy controls (p < 0.001, p = 0.017, p < 0.001 and p = 0.001, respectively). Serum calprotectin and hsCRP levels were higher in diabetics with neuropathy than the ones without (p = 0.021 and p < 0.001, respectively). The positive correlation was detected between calprotectin levels and hsCRP and HbA1c in Spearman correlation analysis (r = 0.510, p < 0.001; r = 0.437, p < 0.001 respectively). The results of multiple logistic regression analysis demonstrated the important association between neuropathy development and hsCRP and serum calprotectin levels in diabetic individuals. Conclusion: Seum calprotectin levels were increased in diabetic peripheral neuropathy. It may have a role in the pathogenesis of the disease. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results